BRIEF—PhoreMost and Arvinas embark on multi-target collab

British firm PhoreMost has entered into a multi-target collaboration with Arvinas, a Connecticut, USA-basesd specialist in targeted protein degradation.

PhoreMost is focused on developing candidates for targets which are generally regarded as being undruggable.

Under the agreement, the company will direct its expertise and phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets.

Arvinas will use the output to drive degrader drug discovery in oncology and neurodegeneration, with its PROTAC discovery engine.

Vice president Angela Cacace said: “Identifying new protein binders is imperative for Arvinas as we expand the capabilities of our PROTAC platform.”

Financial terms were not disclosed.